1cjy › Citations

Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism.

Dessen A, Tang J, Schmidt H, Stahl M, Clark JD, Seehra J, Somers WS
Cell 97 349-60 (1999)
Cited: 213 times
EuropePMC logo PMID: 10319815

Abstract

Cytosolic phospholipase A2 initiates the biosynthesis of prostaglandins, leukotrienes, and platelet-activating factor (PAF), mediators of the pathophysiology of asthma and arthritis. Here, we report the X-ray crystal structure of human cPLA2 at 2.5 A. cPLA2 consists of an N-terminal calcium-dependent lipid-binding/C2 domain and a catalytic unit whose topology is distinct from that of other lipases. An unusual Ser-Asp dyad located in a deep cleft at the center of a predominantly hydrophobic funnel selectively cleaves arachidonyl phospholipids. The structure reveals a flexible lid that must move to allow substrate access to the active site, thus explaining the interfacial activation of this important lipase.

Reviews - 1cjy mentioned but not cited (8)

  1. Using hydrogen/deuterium exchange mass spectrometry to define the specific interactions of the phospholipase A2 superfamily with lipid substrates, inhibitors, and membranes. Cao J, Burke JE, Dennis EA. J Biol Chem 288 1806-1813 (2013)
  2. Review of four major distinct types of human phospholipase A2. Vasquez AM, Mouchlis VD, Dennis EA. Adv Biol Regul 67 212-218 (2018)
  3. Localization and function of cytosolic phospholipase A2alpha at the Golgi. Leslie CC, Gangelhoff TA, Gelb MH. Biochimie 92 620-626 (2010)
  4. Carboxylic ester hydrolases: Classification and database derived from their primary, secondary, and tertiary structures. Chen Y, Black DS, Reilly PJ. Protein Sci 25 1942-1953 (2016)
  5. Membrane and inhibitor interactions of intracellular phospholipases A2. Mouchlis VD, Dennis EA. Adv Biol Regul 61 17-24 (2016)
  6. The Phospholipase A2 Superfamily: Structure, Isozymes, Catalysis, Physiologic and Pathologic Roles. Khan SA, Ilies MA. Int J Mol Sci 24 1353 (2023)
  7. Current Knowledge on Mammalian Phospholipase A1, Brief History, Structures, Biochemical and Pathophysiological Roles. Yaginuma S, Kawana H, Aoki J. Molecules 27 2487 (2022)
  8. Short Peptides for Hydrolase Supramolecular Mimicry and Their Potential Applications. Alletto P, Garcia AM, Marchesan S. Gels 9 678 (2023)

Articles - 1cjy mentioned but not cited (33)

  1. Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. Adler DH, Cogan JD, Phillips JA, Schnetz-Boutaud N, Milne GL, Iverson T, Stein JA, Brenner DA, Morrow JD, Boutaud O, Oates JA. J Clin Invest 118 2121-2131 (2008)
  2. Evaluating caveolin interactions: do proteins interact with the caveolin scaffolding domain through a widespread aromatic residue-rich motif? Byrne DP, Dart C, Rigden DJ. PLoS One 7 e44879 (2012)
  3. VipD of Legionella pneumophila targets activated Rab5 and Rab22 to interfere with endosomal trafficking in macrophages. Ku B, Lee KH, Park WS, Yang CS, Ge J, Lee SG, Cha SS, Shao F, Heo WD, Jung JU, Oh BH. PLoS Pathog 8 e1003082 (2012)
  4. The role of hydrophobic interactions in positioning of peripheral proteins in membranes. Lomize AL, Pogozheva ID, Lomize MA, Mosberg HI. BMC Struct Biol 7 44 (2007)
  5. The minimal domain of adipose triglyceride lipase (ATGL) ranges until leucine 254 and can be activated and inhibited by CGI-58 and G0S2, respectively. Cornaciu I, Boeszoermenyi A, Lindermuth H, Nagy HM, Cerk IK, Ebner C, Salzburger B, Gruber A, Schweiger M, Zechner R, Lass A, Zimmermann R, Oberer M. PLoS One 6 e26349 (2011)
  6. Membranes serve as allosteric activators of phospholipase A2, enabling it to extract, bind, and hydrolyze phospholipid substrates. Mouchlis VD, Bucher D, McCammon JA, Dennis EA. Proc Natl Acad Sci U S A 112 E516-25 (2015)
  7. Location of inhibitors bound to group IVA phospholipase A2 determined by molecular dynamics and deuterium exchange mass spectrometry. Burke JE, Babakhani A, Gorfe AA, Kokotos G, Li S, Woods VL, McCammon JA, Dennis EA. J Am Chem Soc 131 8083-8091 (2009)
  8. Self-induced docking site of a deeply embedded peripheral membrane protein. Jaud S, Tobias DJ, Falke JJ, White SH. Biophys J 92 517-524 (2007)
  9. A phospholipid substrate molecule residing in the membrane surface mediates opening of the lid region in group IVA cytosolic phospholipase A2. Burke JE, Hsu YH, Deems RA, Li S, Woods VL, Dennis EA. J Biol Chem 283 31227-31236 (2008)
  10. Structure of the type III secretion effector protein ExoU in complex with its chaperone SpcU. Halavaty AS, Borek D, Tyson GH, Veesenmeyer JL, Shuvalova L, Minasov G, Otwinowski Z, Hauser AR, Anderson WF. PLoS One 7 e49388 (2012)
  11. The molecular basis of ceramide-1-phosphate recognition by C2 domains. Ward KE, Bhardwaj N, Vora M, Chalfant CE, Lu H, Stahelin RV. J Lipid Res 54 636-648 (2013)
  12. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology. Hart T, Dider S, Han W, Xu H, Zhao Z, Xie L. Sci Rep 6 20441 (2016)
  13. Application of a sensitive collection heuristic for very large protein families: evolutionary relationship between adipose triglyceride lipase (ATGL) and classic mammalian lipases. Schneider G, Neuberger G, Wildpaner M, Tian S, Berezovsky I, Eisenhaber F. BMC Bioinformatics 7 164 (2006)
  14. Modulation of the activity of cytosolic phospholipase A2alpha (cPLA2alpha) by cellular sphingolipids and inhibition of cPLA2alpha by sphingomyelin. Nakamura H, Wakita S, Suganami A, Tamura Y, Hanada K, Murayama T. J Lipid Res 51 720-728 (2010)
  15. Berberine Suppresses Colonic Inflammation in Dextran Sulfate Sodium-Induced Murine Colitis Through Inhibition of Cytosolic Phospholipase A2 Activity. Zhai L, Huang T, Xiao HT, Wu PG, Lin CY, Ning ZW, Zhao L, Kwan HYA, Hu XJ, Wong HLX, Li XQ, Bian ZX. Front Pharmacol 11 576496 (2020)
  16. C2 domain membrane penetration by group IVA cytosolic phospholipase A₂ induces membrane curvature changes. Ward KE, Ropa JP, Adu-Gyamfi E, Stahelin RV. J Lipid Res 53 2656-2666 (2012)
  17. Omega-3 versus Omega-6 fatty acid availability is controlled by hydrophobic site geometries of phospholipase A2s. Hayashi D, Mouchlis VD, Dennis EA. J Lipid Res 62 100113 (2021)
  18. Crystal structure of patatin-17 in complex with aged and non-aged organophosphorus compounds. Wijeyesakere SJ, Richardson RJ, Stuckey JA. PLoS One 9 e108245 (2014)
  19. A New Generation of Arachidonic Acid Analogues as Potential Neurological Agent Targeting Cytosolic Phospholipase A2. Ng CY, Kannan S, Chen YJ, Tan FCK, Ong WY, Go ML, Verma CS, Low CM, Lam Y. Sci Rep 7 13683 (2017)
  20. Pharmacophore-based discovery of a novel cytosolic phospholipase A(2)α inhibitor. Noha SM, Jazzar B, Kuehnl S, Rollinger JM, Stuppner H, Schaible AM, Werz O, Wolber G, Schuster D. Bioorg Med Chem Lett 22 1202-1207 (2012)
  21. The structure of the Ca²+-binding, glycosylated F-spondin domain of F-spondin - A C2-domain variant in an extracellular matrix protein. Tan K, Lawler J. BMC Struct Biol 11 22 (2011)
  22. Wen-Luo-Tong Decoction Attenuates Paclitaxel-Induced Peripheral Neuropathy by Regulating Linoleic Acid and Glycerophospholipid Metabolism Pathways. Wu FZ, Xu WJ, Deng B, Liu SD, Deng C, Wu MY, Gao Y, Jia LQ. Front Pharmacol 9 956 (2018)
  23. Relating the shape of protein binding sites to binding affinity profiles: is there an association? Simon Z, Vigh-Smeller M, Peragovics A, Csukly G, Zahoránszky-Kohalmi G, Rauscher AA, Jelinek B, Hári P, Bitter I, Málnási-Csizmadia A, Czobor P. BMC Struct Biol 10 32 (2010)
  24. 1,4-Disubstituted 1H-1,2,3-Triazoles for Renal Diseases: Studies of Viability, Anti-Inflammatory, and Antioxidant Activities. Cheng CY, Haque A, Hsieh MF, Imran Hassan S, Faizi MSH, Dege N, Khan MS. Int J Mol Sci 21 E3823 (2020)
  25. Associations of maternal PLA2G4C and PLA2G4D polymorphisms with the risk of spontaneous preterm birth in a Chinese population. Liu GJ, He JR, Kuang YS, Fan XJ, Li WD, Lu JH, Xia XY, Liu XD, Chen NN, Mai WB, Xia HM, Qiu X. Mol Med Rep 15 3607-3614 (2017)
  26. The Cytosolic Phospholipase A2α N-terminal C2 Domain Binds and Oligomerizes on Membranes with Positive Curvature. Ward KE, Sengupta R, Ropa JP, Amiar S, Stahelin RV. Biomolecules 10 E647 (2020)
  27. Multiple-docking and affinity fingerprint methods for protein classification and inhibitors selection. Li B, Liu Z, Zhang L, Zhang L. J Chem Inf Model 49 1725-1733 (2009)
  28. The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. Chakraborty S, Rendón-Ramírez A, Ásgeirsson B, Dutta M, Ghosh AS, Oda M, Venkatramani R, Rao BJ, Dandekar AM, Goñi FM. F1000Res 2 286 (2013)
  29. β-Lactones: A Novel Class of Ca2+-Independent Phospholipase A2 (Group VIA iPLA2) Inhibitors with the Ability To Inhibit β-Cell Apoptosis. Dedaki C, Kokotou MG, Mouchlis VD, Limnios D, Lei X, Mu CT, Ramanadham S, Magrioti V, Dennis EA, Kokotos G. J Med Chem 62 2916-2927 (2019)
  30. Two- and three-color STORM analysis reveals higher-order assembly of leukotriene synthetic complexes on the nuclear envelope of murine neutrophils. Schmider AB, Bauer NC, Sunwoo H, Godin MD, Ellis GE, Lee JT, Nigrovic PA, Soberman RJ. J Biol Chem 295 5761-5770 (2020)
  31. A New Strategy for the Rapid Identification and Validation of the Direct Targets of Aconitine-Induced Cardiotoxicity. Wei J, Fan S, Yu H, Shu L, Li Y. Drug Des Devel Ther 15 4649-4664 (2021)
  32. Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson's Disease. Paul S, Fatihi S, Sharma S, Kutum R, Fields R, Pant HC, Thukral L, Bk B. eNeuro 9 ENEURO.0180-22.2022 (2022)
  33. Structure Activity Relationship and Molecular Docking of Some Quinazolines Bearing Sulfamerazine Moiety as New 3CLpro, cPLA2, sPLA2 Inhibitors. Hussein MA, Borik RM, Nafie MS, Abo-Salem HM, Boshra SA, Mohamed ZN. Molecules 28 6052 (2023)


Reviews citing this publication (54)

  1. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Six DA, Dennis EA. Biochim Biophys Acta 1488 1-19 (2000)
  2. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Chem Rev 111 6130-6185 (2011)
  3. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Hauser AR. Nat Rev Microbiol 7 654-665 (2009)
  4. Phospholipase A2 structure/function, mechanism, and signaling. Burke JE, Dennis EA. J Lipid Res 50 Suppl S237-42 (2009)
  5. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Haeggström JZ, Funk CD. Chem Rev 111 5866-5898 (2011)
  6. Phospholipase A2 enzymes. Kudo I, Murakami M. Prostaglandins Other Lipid Mediat 68-69 3-58 (2002)
  7. Lipolysis - a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores. Lass A, Zimmermann R, Oberer M, Zechner R. Prog Lipid Res 50 14-27 (2011)
  8. Phospholipase A2 biochemistry. Burke JE, Dennis EA. Cardiovasc Drugs Ther 23 49-59 (2009)
  9. ExoU is a potent intracellular phospholipase. Sato H, Frank DW. Mol Microbiol 53 1279-1290 (2004)
  10. Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5. Schweiger M, Lass A, Zimmermann R, Eichmann TO, Zechner R. Am J Physiol Endocrinol Metab 297 E289-96 (2009)
  11. Cytosolic phospholipase A₂: physiological function and role in disease. Leslie CC. J Lipid Res 56 1386-1402 (2015)
  12. Synopsis of arachidonic acid metabolism: A review. Hanna VS, Hafez EAA. J Adv Res 11 23-32 (2018)
  13. Lipolysis: pathway under construction. Zechner R, Strauss JG, Haemmerle G, Lass A, Zimmermann R. Curr Opin Lipidol 16 333-340 (2005)
  14. Signaling and subcellular targeting by membrane-binding domains. Hurley JH, Misra S. Annu Rev Biophys Biomol Struct 29 49-79 (2000)
  15. Amphitropic proteins: regulation by reversible membrane interactions (review). Johnson JE, Cornell RB. Mol Membr Biol 16 217-235 (1999)
  16. Regulatory mechanism and physiological role of cytosolic phospholipase A2. Hirabayashi T, Murayama T, Shimizu T. Biol Pharm Bull 27 1168-1173 (2004)
  17. Signaling through C2 domains: more than one lipid target. Corbalan-Garcia S, Gómez-Fernández JC. Biochim Biophys Acta 1838 1536-1547 (2014)
  18. Localization and regulation of cytosolic phospholipase A(2). Hirabayashi T, Shimizu T. Biochim Biophys Acta 1488 124-138 (2000)
  19. Phospholipase A(2) isoforms: a perspective. Chakraborti S. Cell Signal 15 637-665 (2003)
  20. Enzymatic toxins from snake venom: structural characterization and mechanism of catalysis. Kang TS, Georgieva D, Genov N, Murakami MT, Sinha M, Kumar RP, Kaur P, Kumar S, Dey S, Sharma S, Vrielink A, Betzel C, Takeda S, Arni RK, Singh TP, Kini RM. FEBS J 278 4544-4576 (2011)
  21. Membrane binding domains. Hurley JH. Biochim Biophys Acta 1761 805-811 (2006)
  22. Phospholipase A(2). Diaz BL, Arm JP. Prostaglandins Leukot Essent Fatty Acids 69 87-97 (2003)
  23. Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Kita Y, Ohto T, Uozumi N, Shimizu T. Biochim Biophys Acta 1761 1317-1322 (2006)
  24. The G0/G1 switch gene 2 (G0S2): regulating metabolism and beyond. Heckmann BL, Zhang X, Xie X, Liu J. Biochim Biophys Acta 1831 276-281 (2013)
  25. Anionic phospholipids, interfacial binding and the regulation of cell functions. Buckland AG, Wilton DC. Biochim Biophys Acta 1483 199-216 (2000)
  26. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Magrioti V, Kokotos G. Expert Opin Ther Pat 20 1-18 (2010)
  27. Exploring the specific features of interfacial enzymology based on lipase studies. Aloulou A, Rodriguez JA, Fernandez S, van Oosterhout D, Puccinelli D, Carrière F. Biochim Biophys Acta 1761 995-1013 (2006)
  28. Adipose Triglyceride Lipase Regulation: An Overview. Cerk IK, Wechselberger L, Oberer M. Curr Protein Pept Sci 19 221-233 (2018)
  29. Phospholipases A2 in ischemic and toxic brain injury. Sapirstein A, Bonventre JV. Neurochem Res 25 745-753 (2000)
  30. Structure and mechanism of human cytosolic phospholipase A(2). Dessen A. Biochim Biophys Acta 1488 40-47 (2000)
  31. Phospholipase A2 catalysis and lipid mediator lipidomics. Mouchlis VD, Dennis EA. Biochim Biophys Acta Mol Cell Biol Lipids 1864 766-771 (2019)
  32. Phospholipase A2 and phospholipase B activities in fungi. Köhler GA, Brenot A, Haas-Stapleton E, Agabian N, Deva R, Nigam S. Biochim Biophys Acta 1761 1391-1399 (2006)
  33. Protein kinase C: the "masters" of calcium and lipid. Lipp P, Reither G. Cold Spring Harb Perspect Biol 3 a004556 (2011)
  34. Biological effects of secretory phospholipase A(2) group IIA on lipoproteins and in atherogenesis. Jaross W, Eckey R, Menschikowski M. Eur J Clin Invest 32 383-393 (2002)
  35. The story of cell fusion: big lessons from little worms. Shemer G, Podbilewicz B. Bioessays 25 672-682 (2003)
  36. Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction. Cedars A, Jenkins CM, Mancuso DJ, Gross RW. J Cardiovasc Pharmacol 53 277-289 (2009)
  37. Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2. Nikolaou A, Kokotou MG, Vasilakaki S, Kokotos G. Biochim Biophys Acta Mol Cell Biol Lipids 1864 941-956 (2019)
  38. Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present). Magrioti V, Kokotos G. Expert Opin Ther Pat 23 333-344 (2013)
  39. Location, location, location: compartmentalization of early events in leukotriene biosynthesis. Newcomer ME, Gilbert NC. J Biol Chem 285 25109-25114 (2010)
  40. Molecules in focus: cytosolic phospholipase A2-alpha. Niknami M, Patel M, Witting PK, Dong Q. Int J Biochem Cell Biol 41 994-997 (2009)
  41. The cardiac beta2-adrenergic signalling a new role for the cPLA2. Pavoine C, Defer N. Cell Signal 17 141-152 (2005)
  42. Pseudomonas aeruginosa Toxin ExoU as a Therapeutic Target in the Treatment of Bacterial Infections. Foulkes DM, McLean K, Haneef AS, Fernig DG, Winstanley C, Berry N, Kaye SB. Microorganisms 7 E707 (2019)
  43. Roles for cytosolic phospholipase A2alpha as revealed by gene-targeted mice. Uozumi N, Shimizu T. Prostaglandins Other Lipid Mediat 68-69 59-69 (2002)
  44. Recent advances in the regulation of cytosolic phospholipase A(2). Gijón MA, Spencer DM, Leslie CC. Adv Enzyme Regul 40 255-268 (2000)
  45. Floundering about at cell membranes: a structural view of phospholipid signaling. Hurley JH, Tsujishita Y, Pearson MA. Curr Opin Struct Biol 10 737-743 (2000)
  46. Cytosolic phospholipase A2 and the distinct transcriptional programs of astrocytoma cells. Hernández M, Nieto ML, Sánchez Crespo M. Trends Neurosci 23 259-264 (2000)
  47. Eicosanoids: Atherosclerosis and cardiometabolic health. Piper K, Garelnabi M. J Clin Transl Endocrinol 19 100216 (2020)
  48. GPCR activation: protonation and membrane potential. Zhang XC, Sun K, Zhang L, Li X, Cao C. Protein Cell 4 747-760 (2013)
  49. Structural basis of eukaryotic cell targeting by type III secretion system (T3SS) effectors. Tosi T, Pflug A, Discola KF, Neves D, Dessen A. Res Microbiol 164 605-619 (2013)
  50. Phospholipase A(2) enzymes: structural diversity in lipid messenger metabolism. Dessen A. Structure 8 R15-22 (2000)
  51. Plant phospholipases A2: perspectives on biotechnological applications. Mansfeld J. Biotechnol Lett 31 1373-1380 (2009)
  52. Pseudomonas aeruginosa Type III Secretory Toxin ExoU and Its Predicted Homologs. Sawa T, Hamaoka S, Kinoshita M, Kainuma A, Naito Y, Akiyama K, Kato H. Toxins (Basel) 8 E307 (2016)
  53. Membrane proteins: adapting to life at the interface. Hurley JH. Chem Biol 10 2-3 (2003)
  54. Perspectives on the Pseudomonas aeruginosa Type III Secretion System Effector ExoU and Its Subversion of the Host Innate Immune Response to Infection. Hardy KS, Tessmer MH, Frank DW, Audia JP. Toxins (Basel) 13 880 (2021)

Articles citing this publication (118)

  1. The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Yang X, Lu X, Lombès M, Rha GB, Chi YI, Guerin TM, Smart EJ, Liu J. Cell Metab 11 194-205 (2010)
  2. The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. Sato H, Frank DW, Hillard CJ, Feix JB, Pankhaniya RR, Moriyama K, Finck-Barbançon V, Buchaklian A, Lei M, Long RM, Wiener-Kronish J, Sawa T. EMBO J 22 2959-2969 (2003)
  3. Solution structure and dynamics of the outer membrane enzyme PagP by NMR. Hwang PM, Choy WY, Lo EI, Chen L, Forman-Kay JD, Raetz CR, Privé GG, Bishop RE, Kay LE. Proc Natl Acad Sci U S A 99 13560-13565 (2002)
  4. Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. Hefner Y, Borsch-Haubold AG, Murakami M, Wilde JI, Pasquet S, Schieltz D, Ghomashchi F, Yates JR, Armstrong CG, Paterson A, Cohen P, Fukunaga R, Hunter T, Kudo I, Watson SP, Gelb MH. J Biol Chem 275 37542-37551 (2000)
  5. Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca2+. Strokin M, Sergeeva M, Reiser G. Br J Pharmacol 139 1014-1022 (2003)
  6. In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors. Phillips RM, Six DA, Dennis EA, Ghosh P. J Biol Chem 278 41326-41332 (2003)
  7. Metabolic Control of Astrocyte Pathogenic Activity via cPLA2-MAVS. Chao CC, Gutiérrez-Vázquez C, Rothhammer V, Mayo L, Wheeler MA, Tjon EC, Zandee SEJ, Blain M, de Lima KA, Takenaka MC, Avila-Pacheco J, Hewson P, Liu L, Sanmarco LM, Borucki DM, Lipof GZ, Trauger SA, Clish CB, Antel JP, Prat A, Quintana FJ. Cell 179 1483-1498.e22 (2019)
  8. Metal bridges between the PhoQ sensor domain and the membrane regulate transmembrane signaling. Cho US, Bader MW, Amaya MF, Daley ME, Klevit RE, Miller SI, Xu W. J Mol Biol 356 1193-1206 (2006)
  9. The first crystal structure of a phospholipase D. Leiros I, Secundo F, Zambonelli C, Servi S, Hough E. Structure 8 655-667 (2000)
  10. Cloning, expression, purification and characterization of patatin, a novel phospholipase A. Hirschberg HJ, Simons JW, Dekker N, Egmond MR. Eur J Biochem 268 5037-5044 (2001)
  11. Characterization of a novel inhibitor of cytosolic phospholipase A2alpha, pyrrophenone. Ono T, Yamada K, Chikazawa Y, Ueno M, Nakamoto S, Okuno T, Seno K. Biochem J 363 727-735 (2002)
  12. C2 domains of protein kinase C isoforms alpha, beta, and gamma: activation parameters and calcium stoichiometries of the membrane-bound state. Kohout SC, Corbalán-García S, Torrecillas A, Goméz-Fernandéz JC, Falke JJ. Biochemistry 41 11411-11424 (2002)
  13. C2 domains from different Ca2+ signaling pathways display functional and mechanistic diversity. Nalefski EA, Wisner MA, Chen JZ, Sprang SR, Fukuda M, Mikoshiba K, Falke JJ. Biochemistry 40 3089-3100 (2001)
  14. Mechanism of specific membrane targeting by C2 domains: localized pools of target lipids enhance Ca2+ affinity. Corbin JA, Evans JH, Landgraf KE, Falke JJ. Biochemistry 46 4322-4336 (2007)
  15. Differential control of ATGL-mediated lipid droplet degradation by CGI-58 and G0S2. Lu X, Yang X, Liu J. Cell Cycle 9 2719-2725 (2010)
  16. Cryptic proteolytic activity of dihydrolipoamide dehydrogenase. Babady NE, Pang YP, Elpeleg O, Isaya G. Proc Natl Acad Sci U S A 104 6158-6163 (2007)
  17. C2 domain of protein kinase C alpha: elucidation of the membrane docking surface by site-directed fluorescence and spin labeling. Kohout SC, Corbalán-García S, Gómez-Fernández JC, Falke JJ. Biochemistry 42 1254-1265 (2003)
  18. Mechanism of group IVA cytosolic phospholipase A(2) activation by phosphorylation. Das S, Rafter JD, Kim KP, Gygi SP, Cho W. J Biol Chem 278 41431-41442 (2003)
  19. Structure of the C2 domain from novel protein kinase Cepsilon. A membrane binding model for Ca(2+)-independent C2 domains. Ochoa WF, Garcia-Garcia J, Fita I, Corbalan-Garcia S, Verdaguer N, Gomez-Fernandez JC. J Mol Biol 311 837-849 (2001)
  20. Enzymatic properties of human cytosolic phospholipase A(2)gamma. Stewart A, Ghosh M, Spencer DM, Leslie CC. J Biol Chem 277 29526-29536 (2002)
  21. Functional regions of the Pseudomonas aeruginosa cytotoxin ExoU. Rabin SD, Hauser AR. Infect Immun 73 573-582 (2005)
  22. Interfacial membrane docking of cytosolic phospholipase A2 C2 domain using electrostatic potential-modulated spin relaxation magnetic resonance. Ball A, Nielsen R, Gelb MH, Robinson BH. Proc Natl Acad Sci U S A 96 6637-6642 (1999)
  23. Cellular regulation of cytosolic group IV phospholipase A2 by phosphatidylinositol bisphosphate levels. Balsinde J, Balboa MA, Li WH, Llopis J, Dennis EA. J Immunol 164 5398-5402 (2000)
  24. D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Hansford KA, Reid RC, Clark CI, Tyndall JD, Whitehouse MW, Guthrie T, McGeary RP, Schafer K, Martin JL, Fairlie DP. Chembiochem 4 181-185 (2003)
  25. Membrane-docking loops of the cPLA2 C2 domain: detailed structural analysis of the protein-membrane interface via site-directed spin-labeling. Malmberg NJ, Van Buskirk DR, Falke JJ. Biochemistry 42 13227-13240 (2003)
  26. Molecular imaging of membrane interfaces reveals mode of beta-glucosidase activation by saposin C. Alattia JR, Shaw JE, Yip CM, Privé GG. Proc Natl Acad Sci U S A 104 17394-17399 (2007)
  27. Hypotonic cell swelling induces translocation of the alpha isoform of cytosolic phospholipase A2 but not the gamma isoform in Ehrlich ascites tumor cells. Pedersen S, Lambert IH, Thoroed SM, Hoffmann EK. Eur J Biochem 267 5531-5539 (2000)
  28. Structural basis of cytotoxicity mediated by the type III secretion toxin ExoU from Pseudomonas aeruginosa. Gendrin C, Contreras-Martel C, Bouillot S, Elsen S, Lemaire D, Skoufias DA, Huber P, Attree I, Dessen A. PLoS Pathog 8 e1002637 (2012)
  29. Localizing the membrane binding region of Group VIA Ca2+-independent phospholipase A2 using peptide amide hydrogen/deuterium exchange mass spectrometry. Hsu YH, Burke JE, Li S, Woods VL, Dennis EA. J Biol Chem 284 23652-23661 (2009)
  30. Phosphatidylinositol 4,5-bisphosphate anchors cytosolic group IVA phospholipase A2 to perinuclear membranes and decreases its calcium requirement for translocation in live cells. Casas J, Gijón MA, Vigo AG, Crespo MS, Balsinde J, Balboa MA. Mol Biol Cell 17 155-162 (2006)
  31. The Salmonella SPI-2 effector SseJ exhibits eukaryotic activator-dependent phospholipase A and glycerophospholipid : cholesterol acyltransferase activity. Lossi NS, Rolhion N, Magee AI, Boyle C, Holden DW. Microbiology (Reading) 154 2680-2688 (2008)
  32. The calcium binding loops of the cytosolic phospholipase A2 C2 domain specify targeting to Golgi and ER in live cells. Evans JH, Gerber SH, Murray D, Leslie CC. Mol Biol Cell 15 371-383 (2004)
  33. Characterization of phospholipase activity of the Pseudomonas aeruginosa type III cytotoxin, ExoU. Sato H, Feix JB, Hillard CJ, Frank DW. J Bacteriol 187 1192-1195 (2005)
  34. The cytosolic phospholipase A2 catalytic domain modulates association and residence time at Golgi membranes. Evans JH, Leslie CC. J Biol Chem 279 6005-6016 (2004)
  35. Differential inhibition of group IVA and group VIA phospholipases A2 by 2-oxoamides. Stephens D, Barbayianni E, Constantinou-Kokotou V, Peristeraki A, Six DA, Cooper J, Harkewicz R, Deems RA, Dennis EA, Kokotos G. J Med Chem 49 2821-2828 (2006)
  36. Characterization of desnutrin functional domains: critical residues for triacylglycerol hydrolysis in cultured cells. Duncan RE, Wang Y, Ahmadian M, Lu J, Sarkadi-Nagy E, Sul HS. J Lipid Res 51 309-317 (2010)
  37. The structure of iPLA2β reveals dimeric active sites and suggests mechanisms of regulation and localization. Malley KR, Koroleva O, Miller I, Sanishvili R, Jenkins CM, Gross RW, Korolev S. Nat Commun 9 765 (2018)
  38. Calcium binding rigidifies the C2 domain and the intradomain interaction of GIVA phospholipase A2 as revealed by hydrogen/deuterium exchange mass spectrometry. Hsu YH, Burke JE, Stephens DL, Deems RA, Li S, Asmus KM, Woods VL, Dennis EA. J Biol Chem 283 9820-9827 (2008)
  39. Inhibition of the MEK1/ERK pathway reduces arachidonic acid release independently of cPLA2 phosphorylation and translocation. Evans JH, Fergus DJ, Leslie CC. BMC Biochem 3 30 (2002)
  40. Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Kumar R, Coronel L, Somalanka B, Raju A, Aning OA, An O, Ho YS, Chen S, Mak SY, Hor PY, Yang H, Lakshmanan M, Itoh H, Tan SY, Lim YK, Wong APC, Chew SH, Huynh TH, Goh BC, Lim CY, Tergaonkar V, Cheok CF. Nat Commun 9 3931 (2018)
  41. A patatin-like protein protects Toxoplasma gondii from degradation in a nitric oxide-dependent manner. Tobin CM, Knoll LJ. Infect Immun 80 55-61 (2012)
  42. Role of phosphorylation and basic residues in the catalytic domain of cytosolic phospholipase A2alpha in regulating interfacial kinetics and binding and cellular function. Tucker DE, Ghosh M, Ghomashchi F, Loper R, Suram S, John BS, Girotti M, Bollinger JG, Gelb MH, Leslie CC. J Biol Chem 284 9596-9611 (2009)
  43. Crystal structure of a family 4 uracil-DNA glycosylase from Thermus thermophilus HB8. Hoseki J, Okamoto A, Masui R, Shibata T, Inoue Y, Yokoyama S, Kuramitsu S. J Mol Biol 333 515-526 (2003)
  44. A two-helix motif positions the lysophosphatidic acid acyltransferase active site for catalysis within the membrane bilayer. Robertson RM, Yao J, Gajewski S, Kumar G, Martin EW, Rock CO, White SW. Nat Struct Mol Biol 24 666-671 (2017)
  45. Structural and mutational analysis of the nonribosomal peptide synthetase heterocyclization domain provides insight into catalysis. Bloudoff K, Fage CD, Marahiel MA, Schmeing TM. Proc Natl Acad Sci U S A 114 95-100 (2017)
  46. A patatin-like protein protects Toxoplasma gondii from degradation in activated macrophages. Mordue DG, Scott-Weathers CF, Tobin CM, Knoll LJ. Mol Microbiol 63 482-496 (2007)
  47. Ubiquitin activates patatin-like phospholipases from multiple bacterial species. Anderson DM, Sato H, Dirck AT, Feix JB, Frank DW. J Bacteriol 197 529-541 (2015)
  48. Discovery of novel membrane binding structures and functions. Kufareva I, Lenoir M, Dancea F, Sridhar P, Raush E, Bissig C, Gruenberg J, Abagyan R, Overduin M. Biochem Cell Biol 92 555-563 (2014)
  49. Identification of the expressed form of human cytosolic phospholipase A2beta (cPLA2beta): cPLA2beta3 is a novel variant localized to mitochondria and early endosomes. Ghosh M, Loper R, Gelb MH, Leslie CC. J Biol Chem 281 16615-16624 (2006)
  50. Structural basis for the recruitment and activation of the Legionella phospholipase VipD by the host GTPase Rab5. Lucas M, Gaspar AH, Pallara C, Rojas AL, Fernández-Recio J, Machner MP, Hierro A. Proc Natl Acad Sci U S A 111 E3514-23 (2014)
  51. The patatin-like lipase family in Gallus gallus. Saarela J, Jung G, Hermann M, Nimpf J, Schneider WJ. BMC Genomics 9 281 (2008)
  52. Modeling the tertiary structure of the patatin domain of neuropathy target esterase. Wijeyesakere SJ, Richardson RJ, Stuckey JA. Protein J 26 165-172 (2007)
  53. Involvement of multiple protein kinases in cPLA2 phosphorylation, arachidonic acid release, and cell death in in vivo and in vitro models of 1-methyl-4-phenylpyridinium-induced parkinsonism--the possible key role of PKG. Chalimoniuk M, Stolecka A, Ziemińska E, Stepień A, Langfort J, Strosznajder JB. J Neurochem 110 307-317 (2009)
  54. Solution structure of the N-terminal catalytic domain of human H-REV107--a novel circular permutated NlpC/P60 domain. Ren X, Lin J, Jin C, Xia B. FEBS Lett 584 4222-4226 (2010)
  55. Acceleration by ceramide of calcium-dependent translocation of phospholipase A2 from cytosol to membranes in platelets. Kitatani K, Oka T, Murata T, Hayama M, Akiba S, Sato T. Arch Biochem Biophys 382 296-302 (2000)
  56. Activation of ExoU phospholipase activity requires specific C-terminal regions. Schmalzer KM, Benson MA, Frank DW. J Bacteriol 192 1801-1812 (2010)
  57. Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A2 Guided by Molecular Dynamics and Structure-Activity Relationships. Mouchlis VD, Limnios D, Kokotou MG, Barbayianni E, Kokotos G, McCammon JA, Dennis EA. J Med Chem 59 4403-4414 (2016)
  58. Cytosolic phospholipase A2alpha activation induced by S1P is mediated by the S1P3 receptor in lung epithelial cells. Chen LY, Woszczek G, Nagineni S, Logun C, Shelhamer JH. Am J Physiol Lung Cell Mol Physiol 295 L326-35 (2008)
  59. Cytosolic phospholipase A2: a member of the signalling pathway of a new G protein alpha subunit in Sporothrix schenckii. Valentín-Berríos S, González-Velázquez W, Pérez-Sánchez L, González-Méndez R, Rodríguez-Del Valle N. BMC Microbiol 9 100 (2009)
  60. Identification of phospholipase B from Dictyostelium discoideum reveals a new lipase family present in mammals, flies and nematodes, but not yeast. Morgan CP, Insall R, Haynes L, Cockcroft S. Biochem J 382 441-449 (2004)
  61. Structural basis of phosphatidylcholine recognition by the C2-domain of cytosolic phospholipase A2α. Hirano Y, Gao YG, Stephenson DJ, Vu NT, Malinina L, Simanshu DK, Chalfant CE, Patel DJ, Brown RE. Elife 8 e44760 (2019)
  62. 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Forster L, Ludwig J, Kaptur M, Bovens S, Elfringhoff AS, Holtfrerich A, Lehr M. Bioorg Med Chem 18 945-952 (2010)
  63. Class assignment of sequence-unrelated members of enzyme superfamilies by activity-based protein profiling. Jessani N, Young JA, Diaz SL, Patricelli MP, Varki A, Cravatt BF. Angew Chem Int Ed Engl 44 2400-2403 (2005)
  64. Cooperative Substrate-Cofactor Interactions and Membrane Localization of the Bacterial Phospholipase A2 (PLA2) Enzyme, ExoU. Tessmer MH, Anderson DM, Buchaklian A, Frank DW, Feix JB. J Biol Chem 292 3411-3419 (2017)
  65. The pepper patatin-like phospholipase CaPLP1 functions in plant cell death and defense signaling. Kim DS, Jeun Y, Hwang BK. Plant Mol Biol 84 329-344 (2014)
  66. Understanding traditional Chinese medicine anti-inflammatory herbal formulae by simulating their regulatory functions in the human arachidonic acid metabolic network. Gu S, Yin N, Pei J, Lai L. Mol Biosyst 9 1931-1938 (2013)
  67. The SpoMBe pathway drives membrane bending necessary for cytokinesis and spore formation in yeast meiosis. Maier P, Rathfelder N, Maeder CI, Colombelli J, Stelzer EH, Knop M. EMBO J 27 2363-2374 (2008)
  68. Ca2+ activation of the cPLA2 C2 domain: ordered binding of two Ca2+ ions with positive cooperativity. Malmberg NJ, Varma S, Jakobsson E, Falke JJ. Biochemistry 43 16320-16328 (2004)
  69. Catalytic residues of group VIB calcium-independent phospholipase A2 (iPLA2gamma). Tanaka H, Minakami R, Kanaya H, Sumimoto H. Biochem Biophys Res Commun 320 1284-1290 (2004)
  70. Cofactor-independent phosphoglycerate mutase from nematodes has limited druggability, as revealed by two high-throughput screens. Crowther GJ, Booker ML, He M, Li T, Raverdy S, Novelli JF, He P, Dale NR, Fife AM, Barker RH, Kramer ML, Van Voorhis WC, Carlow CK, Wang MW. PLoS Negl Trop Dis 8 e2628 (2014)
  71. Crystal structure of plant PLDα1 reveals catalytic and regulatory mechanisms of eukaryotic phospholipase D. Li J, Yu F, Guo H, Xiong R, Zhang W, He F, Zhang M, Zhang P. Cell Res 30 61-69 (2020)
  72. Galpha13 mediates activation of the cytosolic phospholipase A2alpha through fine regulation of ERK phosphorylation. Mariggiò S, Bavec A, Natale E, Zizza P, Salmona M, Corda D, Di Girolamo M. Cell Signal 18 2200-2208 (2006)
  73. Lysophosphatidylcholine hydrolases of human erythrocytes, lymphocytes, and brain: sensitive targets of conserved specificity for organophosphorus delayed neurotoxicants. Vose SC, Holland NT, Eskenazi B, Casida JE. Toxicol Appl Pharmacol 224 98-104 (2007)
  74. Structural characterization of the C2 domain of novel protein kinase Cepsilon. García-García J, Gómez-Fernández JC, Corbalán-García S. Eur J Biochem 268 1107-1117 (2001)
  75. Substrate-Specific Inhibition Constants for Phospholipase A2 Acting on Unique Phospholipid Substrates in Mixed Micelles and Membranes Using Lipidomics. Mouchlis VD, Armando A, Dennis EA. J Med Chem 62 1999-2007 (2019)
  76. The crystal structure analysis of group B Streptococcus sortase C1: a model for the "lid" movement upon substrate binding. Khare B, Fu ZQ, Huang IH, Ton-That H, Narayana SV. J Mol Biol 414 563-577 (2011)
  77. PGE2 release is independent of upregulation of Group V phospholipase A2 during long-term stimulation of P388D1 cells with LPS. Kessen UA, Schaloske RH, Stephens DL, Killermann Lucas K, Dennis EA. J Lipid Res 46 2488-2496 (2005)
  78. Comment Preventing injury from within, using selective cPLA2 inhibitors. Serhan CN. Nat Immunol 1 13-15 (2000)
  79. A novel patatin-like protein from cotton plant, GhPat1, is co-expressed with GhLox1 during Xanthomonas campestris-mediated hypersensitive cell death. Cacas JL, Marmey P, Montillet JL, Sayegh-Alhamdia M, Jalloul A, Rojas-Mendoza A, Clérivet A, Nicole M. Plant Cell Rep 28 155-164 (2009)
  80. Retraction of Publication An inhibitor of O-glycosylation induces apoptosis in NIH3T3 cells and developing mouse embryonic mandibular tissues. Tian E, Ten Hagen KG, Shum L, Hang HC, Imbert Y, Young WW, Bertozzi CR, Tabak LA. J Biol Chem 283 4460 (2008)
  81. Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. Kirincich SJ, Xiang J, Green N, Tam S, Yang HY, Shim J, Shen MW, Clark JD, McKew JC. Bioorg Med Chem 17 4383-4405 (2009)
  82. Binding conformation of 2-oxoamide inhibitors to group IVA cytosolic phospholipase A2 determined by molecular docking combined with molecular dynamics. Mouchlis VD, Michopoulou V, Constantinou-Kokotou V, Mavromoustakos T, Dennis EA, Kokotos G. J Chem Inf Model 52 243-254 (2012)
  83. Functional characterization of mutations in inherited human cPLA₂ deficiency. Reed KA, Tucker DE, Aloulou A, Adler D, Ghomashchi F, Gelb MH, Leslie CC, Oates JA, Boutaud O. Biochemistry 50 1731-1738 (2011)
  84. Structure-activity relationships of indole cytosolic phospholipase A(2)alpha inhibitors: substrate mimetics. McKew JC, Lovering F, Clark JD, Bemis J, Xiang Y, Shen M, Zhang W, Alvarez JC, Joseph-McCarthy D. Bioorg Med Chem Lett 13 4501-4504 (2003)
  85. Synthesis and activity of 2-oxoamides containing long chain beta-amino acids. Constantinou-Kokotou V, Peristeraki A, Kokotos CG, Six DA, Dennis EA. J Pept Sci 11 431-435 (2005)
  86. 1-(3-biaryloxy-2-oxopropyl)indole-5-carboxylic acids and related compounds as dual inhibitors of human cytosolic phospholipase A2α and fatty acid amide hydrolase. Zahov S, Drews A, Hess M, Schulze Elfringhoff A, Lehr M. ChemMedChem 6 544-549 (2011)
  87. 2-Oxoesters: A Novel Class of Potent and Selective Inhibitors of Cytosolic Group IVA Phospholipase A2. Kokotou MG, Galiatsatou G, Magrioti V, Koutoulogenis G, Barbayianni E, Limnios D, Mouchlis VD, Satpathy B, Navratil A, Dennis EA, Kokotos G. Sci Rep 7 7025 (2017)
  88. Polychlorinated biphenyls induce arachidonic acid release in human platelets in a tamoxifen sensitive manner via activation of group IVA cytosolic phospholipase A2-alpha. Forsell PK, Olsson AO, Andersson E, Nallan L, Gelb MH. Biochem Pharmacol 71 144-155 (2005)
  89. A toxoplasma patatin-like protein changes localization and alters the cytokine response during toxoplasmic encephalitis. Tobin Magle C, Pittman KJ, Moser LA, Boldon KM, Knoll LJ. Infect Immun 82 618-625 (2014)
  90. Interactions of the effector ExoU from Pseudomonas aeruginosa with short-chain phosphatidylinositides provide insights into ExoU targeting to host membranes. Springer TI, Reid TE, Gies SL, Feix JB. J Biol Chem 294 19012-19021 (2019)
  91. N-terminal and C-terminal plasma membrane anchoring modulate differently agonist-induced activation of cytosolic phospholipase A2. Klapisz E, Ziari M, Wendum D, Koumanov K, Brachet-Ducos C, Olivier JL, Béréziat G, Trugnan G, Masliah J. Eur J Biochem 265 957-966 (1999)
  92. Substrate efflux propensity plays a key role in the specificity of secretory A-type phospholipases. Haimi P, Hermansson M, Batchu KC, Virtanen JA, Somerharju P. J Biol Chem 285 751-760 (2010)
  93. The functional implications of the dimerization of the catalytic subunits of the mammalian brain platelet-activating factor acetylhydrolase (Ib). McMullen TW, Li J, Sheffield PJ, Aoki J, Martin TW, Arai H, Inoue K, Derewenda ZS. Protein Eng 13 865-871 (2000)
  94. 1,2,4-Oxadiazolidin-3,5-diones and 1,3,5-triazin-2,4,6-triones as cytosolic phospholipase A2alpha inhibitors. Gopalsamy A, Yang H, Ellingboe JW, McKew JC, Tam S, Joseph-McCarthy D, Zhang W, Shen M, Clark JD. Bioorg Med Chem Lett 16 2978-2981 (2006)
  95. Identification and Verification of Ubiquitin-Activated Bacterial Phospholipases. Tessmer MH, Anderson DM, Pickrum AM, Riegert MO, Frank DW. J Bacteriol 201 e00623-18 (2019)
  96. Characterization of the ExoU activation mechanism using EPR and integrative modeling. Tessmer MH, DeCero SA, Del Alamo D, Riegert MO, Meiler J, Frank DW, Feix JB. Sci Rep 10 19700 (2020)
  97. Guinea pig phospholipase B, identification of the catalytic serine and the proregion involved in its processing and enzymatic activity. Nauze M, Gonin L, Chaminade B, Perès C, Hullin-Matsuda F, Perret B, Chap H, Gassama-Diagne A. J Biol Chem 277 44093-44099 (2002)
  98. Regulation of cytosolic phospholipase A(2) translocation. Evans JH, Fergus DJ, Leslie CC. Adv Enzyme Regul 43 229-244 (2003)
  99. The cPLA2 C2alpha domain in solution: structure and dynamics of its Ca2+-activated and cation-free states. Varma S, Jakobsson E. Biophys J 92 966-976 (2007)
  100. Mechanism-based inhibition of iPLA2β demonstrates a highly reactive cysteine residue (C651) that interacts with the active site: mass spectrometric elucidation of the mechanisms underlying inhibition. Jenkins CM, Yang J, Gross RW. Biochemistry 52 4250-4263 (2013)
  101. Off-target effect of the cPLA2α inhibitor pyrrophenone: Inhibition of calcium release from the endoplasmic reticulum. Yun B, Lee H, Ewing H, Gelb MH, Leslie CC. Biochem Biophys Res Commun 479 61-66 (2016)
  102. Redefining the architecture of ferlin proteins: Insights into multi-domain protein structure and function. Dominguez MJ, McCord JJ, Sutton RB. PLoS One 17 e0270188 (2022)
  103. Synthesis and Evaluation of Cytosolic Phospholipase A(2) Activatable Fluorophores for Cancer Imaging. Chiorazzo MG, Bloch NB, Popov AV, Delikatny EJ. Bioconjug Chem 26 2360-2370 (2015)
  104. Role of phosphatidylinositol 4,5-bisphosphate in the activation of cytosolic phospholipase A2-alpha. Le Berre L, Takano T, Papillon J, Lemay S, Cybulsky AV. Prostaglandins Other Lipid Mediat 81 113-125 (2006)
  105. Selectivity of cytosolic phospholipase A2 type IV toward arachidonyl phospholipids. Grandits M, Oostenbrink C. J Mol Recognit 28 447-457 (2015)
  106. Thermodynamic characterization of cytosolic phospholipase A2 alpha inhibitors. Ramarao MK, Shen MW, Murphy EA, Duan W, Zhao Y, McKew J, Lee KL, Thakker P, Behnke ML, Clark JD. Anal Biochem 383 217-225 (2008)
  107. Cation charge and size selectivity of the C2 domain of cytosolic phospholipase A(2). Nalefski EA, Falke JJ. Biochemistry 41 1109-1122 (2002)
  108. Membrane Association Allosterically Regulates Phospholipase A2 Enzymes and Their Specificity. Mouchlis VD, Dennis EA. Acc Chem Res 55 3303-3311 (2022)
  109. Design of novel and potent cPLA2α inhibitors containing an α-methyl-2-ketothiazole as a metabolically stable serine trap. Mete A, Andrews G, Bernstein M, Connolly S, Hartopp P, Jackson CG, Lewis R, Martin I, Murray D, Riley R, Robinson DH, Smith GM, Wells E, Withnall WJ. Bioorg Med Chem Lett 21 3128-3133 (2011)
  110. The development of an ELISA for group IVA phospholipase A2 in human red blood cells. Macdonald DJ, Boyle RM, Glen AC, Leslie CC, Glen AI, Horrobin DF. Prostaglandins Leukot Essent Fatty Acids 94 43-48 (2015)
  111. Active site remodelling of a cyclodipeptide synthase redefines substrate scope. Sutherland E, Harding CJ, Czekster CM. Commun Chem 5 101 (2022)
  112. Comprehensive identification and functional characterization of GhpPLA gene family in reproductive organ development. Wang M, Tian D, Li T, Pan J, Wang C, Wu L, Luo K, Mei Z, Liu J, Chen W, Yao J, Li Y, Wang F, Zhu S, Zhang Y. BMC Plant Biol 23 599 (2023)
  113. Computational Modeling Study of the Binding of Aging and Non-Aging Inhibitors with Neuropathy Target Esterase. Wu W, Wang P. Molecules 28 7747 (2023)
  114. Gypenoside L and Gypenoside LI Inhibit Proliferation in Renal Cell Carcinoma via Regulation of the MAPK and Arachidonic Acid Metabolism Pathways. Liu H, Li X, Xie J, Lv C, Lian F, Zhang S, Duan Y, Zeng Y, Piao X. Front Pharmacol 13 820639 (2022)
  115. Identification of motifs and mechanisms for lipid droplet targeting of the lipolytic inhibitors G0S2 and HIG2. Campbell LE, Anderson AM, Chen Y, Johnson SM, McMahon CE, Liu J. J Cell Sci 135 jcs260236 (2022)
  116. Insights into the mechanism of phospholipid hydrolysis by plant non-specific phospholipase C. Fan R, Zhao F, Gong Z, Chen Y, Yang B, Zhou C, Zhang J, Du Z, Wang X, Yin P, Guo L, Liu Z. Nat Commun 14 194 (2023)
  117. Purification of Cytosolic Phospholipase A2α C2-domain after Expression in Soluble Form in Escherichia coli. Hirano Y, Gao YG, K Simanshu D, J Stephenson D, T Vu N, Malinina L, E Chalfant C, J Patel D, E Brown R. Bio Protoc 11 e3906 (2021)
  118. Synthesis, activity and metabolic stability of propan-2-one substituted tetrazolylalkanoic acids as dual inhibitors of cytosolic phospholipase A2α and fatty acid amide hydrolase. Ekodo Voundi M, Hanekamp W, Lehr M. RSC Med Chem 14 2079-2088 (2023)


Quick links